BWS 7
Alternative Names: BWS-7Latest Information Update: 04 Feb 2025
Price :
$50 *
At a glance
- Originator Argo Biopharma
- Class Antiparkinsonians; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 30 Jan 2025 BWS 7 is available for licensing as of 30 Jan 2025. https://www.argobiopharma.com/partnering/index.html (Argo Biopharma pipeline, January 2025)
- 30 Jan 2025 Preclinical trials in Parkinson's disease in China (Parenteral), before January 2025 (Argo Biopharma pipeline, January 2025)